Evidence map›Paper›PMID 37688596›Full record

ArticleApplied microbiology and biotechnology2023

Novel findings about the mode of action of the antifungal protein PeAfpA against Saccharomyces cerevisiae.

Moisés Giner-Llorca, Antonella Locascio, Javier Alonso Del Real, Jose F Marcos, Paloma Manzanares

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Morphotype-specific susceptibility toMicrobiology spectrum · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Moisés Giner-LlorcaDepartment of Food Biotechnology, Instituto de Agroquímica y Tecnología de Alimentos (IATA), Consejo Superior de Investigaciones Científicas (CSIC), Catedrático Agustín Escardino 7, Paterna, Valencia, 46980, Spain.ORCID http://orcid.org/0000-0001-5765-9795
Antonella LocascioDepartment of Food Biotechnology, Instituto de Agroquímica y Tecnología de Alimentos (IATA), Consejo Superior de Investigaciones Científicas (CSIC), Catedrático Agustín Escardino 7, Paterna, Valencia, 46980, Spain.ORCID http://orcid.org/0000-0001-8026-1937
Javier Alonso Del RealDepartment of Food Biotechnology, Instituto de Agroquímica y Tecnología de Alimentos (IATA), Consejo Superior de Investigaciones Científicas (CSIC), Catedrático Agustín Escardino 7, Paterna, Valencia, 46980, Spain.ORCID http://orcid.org/0000-0002-6474-9040
Jose F MarcosDepartment of Food Biotechnology, Instituto de Agroquímica y Tecnología de Alimentos (IATA), Consejo Superior de Investigaciones Científicas (CSIC), Catedrático Agustín Escardino 7, Paterna, Valencia, 46980, Spain.ORCID http://orcid.org/0000-0003-3339-2584
Paloma ManzanaresDepartment of Food Biotechnology, Instituto de Agroquímica y Tecnología de Alimentos (IATA), Consejo Superior de Investigaciones Científicas (CSIC), Catedrático Agustín Escardino 7, Paterna, Valencia, 46980, Spain. pmanz@iata.csic.es.ORCID http://orcid.org/0000-0001-5036-9787
Consejo Superior de Investigaciones Científicas · ES

Funding

Ministerio de Ciencia e Innovación CEX2021-001189-SMinisterio de Ciencia e Innovación FPU19/02066Ministerio de Ciencia e Innovación PID2021-125858OB-100Ministerio de Ciencia e Innovación RTI2018-101115-B-C21
6 · The paper itself

Abstract

Antifungal proteins (AFPs) from filamentous fungi offer the potential to control fungal infections that threaten human health and food safety. AFPs exhibit broad antifungal spectra against harmful fungi, but limited knowledge of their killing mechanism hinders their potential applicability. PeAfpA from Penicillium expansum shows strong antifungal potency against plant and human fungal pathogens and stands above other AFPs for being active against the yeast Saccharomyces cerevisiae. We took advantage of this and used a model laboratory strain of S. cerevisiae to gain insight into the mode of action of PeAfpA by combining (i) transcriptional profiling, (ii) PeAfpA sensitivity analyses of deletion mutants available in the S. cerevisiae genomic deletion collection and (iii) cell biology studies using confocal microscopy. Results highlighted and confirmed the role of the yeast cell wall (CW) in the interaction with PeAfpA, which can be internalized through both energy-dependent and independent mechanisms. The combined results also suggest an active role of the CW integrity (CWI) pathway and the cAMP-PKA signalling in the PeAfpA killing mechanism. Besides, our studies revealed the involvement of phosphatidylinositol metabolism and the participation of ROX3, which codes for the subunit 19 of the RNA polymerase II mediator complex, in the yeast defence strategy. In conclusion, our study provides clues about both the killing mechanism of PeAfpA and the fungus defence strategies against the protein, suggesting also targets for the development of new antifungals. KEY POINTS: • PeAfpA is a cell-penetrating protein with inhibitory activity against S. cerevisiae. • The CW integrity (CWI) pathway is a key player in the PeAfpA killing mechanism. • Phosphatidylinositol metabolism and ROX3 are involved in the yeast defence strategy.

Indexed as

Antifungal AgentsFungal ProteinsPenicilliumSaccharomyces cerevisiaeCell WallGene Expression ProfilingSaccharomyces cerevisiae ProteinsAntifungal AgentsFungal ProteinsSaccharomyces cerevisiae ProteinsAntifungal proteins (AFPs)Cell-penetrating proteinCell wall integrityPhosphatidylinositol metabolismTranscriptomicsYeast deletion collection

Identifiers

PMID37688596
PMCPMC10589166
OpenAlexW4386569569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.